Biotech 2050 Podcast cover image

Biotech 2050 Podcast

Latest episodes

undefined
Feb 7, 2024 • 46min

Psychedelics, Longevity, and Wellbeing, Christian Angermayer, Founder, Apeiron Investment Group

Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making biotech more accessible to a broader audience while maintaining the integrity of the science. He discusses the need for a broader investor community in biotech to unlock more capital and stimulate early-stage science funding. His unique perspective highlights the intersection of tech and biotech, emphasizing the potential for collaboration and innovation. By implementing Angermayer's insights, entrepreneurs can gain a comprehensive understanding of the evolving landscape of biotech and harness new opportunities for growth and development. By incorporating Angermayer's insights, entrepreneurs can gain essential knowledge of the evolving biotech landscape and capitalize on new opportunities for growth and development. Biography: Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives. Christian’s family office and private investment firm, Apeiron Investment Group, has more than USD 2.5 billion under management and 50 people in London, New York City, Abu Dhabi and Berlin. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Experiences, Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns himself and has been the lead investor in four unicorns and two decacorns.
undefined
Jan 31, 2024 • 34min

Navigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT

David Kirn, CEO of 4D Molecular Therapeutics, discusses the development of their gene therapy platform and the tension between platform and product focus. He emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase success. The episode also explores fundraising, regional dynamics of biotech investment, and the benefits of a common technology stack in therapeutic development.
undefined
Jan 10, 2024 • 26min

Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics

CEO of ONL Therapeutics, David Esposito, discusses challenges and opportunities in ophthalmology, including the impact of the Inflation Reduction Act (IRA) on indication selection and the evolving capital market for biotech companies. They also talk about proving safety and tolerability in new mechanisms of action, shifting towards chronic indications, and the relationship between big pharma and early-stage biotechs. Essential listening for ophthalmology professionals seeking to navigate industry challenges and understand the IRA's implications.
undefined
9 snips
Dec 13, 2023 • 26min

Overcoming Capital Challenges in Biotech, Jak Knowles, President & CEO, Affini-T Therapeutics

Jak Knowles, President & CEO, Affini-T Therapeutics, shares insights on capital challenges in biotech, importance of key partners, early IP, experienced investors, and Affini-T's innovative approach to solid tumors using cell therapy and synthetic biology. Essential for biotech entrepreneurs.
undefined
Dec 6, 2023 • 20min

A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema since then, including an update on their lead product candidate. Sean reflects on navigating the challenging biotech market environment over the past year, making careful spending decisions, and raising significant capital to extend Olema’s runway. He also offers advice to first-time CEOs on building a strong support network to guide company growth. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.
undefined
Nov 29, 2023 • 33min

The promise of precision oncology, Troy Wilson, President & CEO, Kura Oncology

Synopsis: Troy Wilson, Ph.D., J.D., is the President and CEO of Kura Oncology, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Troy talks about his experiences being a CEO and the differences in responsibility between being a CEO and a board member. He also shares what it takes to have a productive board for a biotech company. He discusses recruiting at both the team level and the board level and the qualities that he looks for in a candidate. He shares where he thinks cancer drug development is headed, where it needs to head and where he thinks there’s unmet need. Finally, he talks about the work they’re pursuing at Kura and where they are from a development perspective. Biography: Troy E. Wilson, Ph.D., J.D., is one of Kura’s Co-founders and has served as our President and Chief Executive Officer and as the Chairman of our Board of Directors since our inception in August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publicly held biopharmaceutical company, since October 2013, Chairman and a member of the Board of Directors of Avidity Biosciences, Inc., a publicly held biopharmaceutical company, since February 2019 and November 2012, respectively, Executive Chairman and a member of the Board of Directors of Wellspring Biosciences since February 2019 and July 2012, respectively, and a member of the Board of Managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.
undefined
Nov 22, 2023 • 41min

Next-gen gene editing, Keith Gottesdiener, President & CEO, Jeremy Duffield, CSO, Prime Medicine

Keith Gottesdiener, President & CEO, and Jeremy Duffield, CSO, of Prime Medicine, discuss their career journeys, differences between big pharma and biotech, pursuing curative treatments using gene editing, building a motivated team at Prime Medicine, and advice for young biotech professionals.
undefined
Nov 15, 2023 • 41min

Developing medicines for broad populations of cancer patients, Brett Hall, CSO, Immuneering

Brett Hall, CSO of Immuneering, talks about military experience influencing drug development. He discusses the use of AI in predicting protein interactions and the pros and cons of being a private or public company. The likelihood of repealing pharmaceutical provisions and concerns for the next generation of scientists are also explored.
undefined
Nov 8, 2023 • 26min

Harnessing the power of microglia, Ivana Magovčević-Liebisch, President & CEO, Vigil Neuroscience

Ivana Magovčević-Liebisch, President and CEO of Vigil Neuroscience, discusses the evolution of her role at the company, the importance of diversity in leadership, and the challenges and opportunities in precision-based neurology. She also shares insights on building a strong team and culture, the potential of microglia biology, and the importance of patient-centricity in the biotech sector.
undefined
Nov 1, 2023 • 27min

Revolutionizing eyecare treatment, Bobak Azamian, CEO & Chairman, Tarsus Pharmaceuticals

Bobak Azamian, CEO and Chairman of Tarsus Pharmaceuticals, talks about revolutionizing eyecare treatment. He discusses unmet needs and patient focus, future indications they're pursuing, and leveraging learnings from previous programs. He also shares the challenges of going public during the pandemic. The podcast covers their recent product approval and the impact it had on the team, their approach to treating Blevveritis, preparing for commercialization, and the changes and challenges of leading a commercial stage company.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode